The majority of patients with head and neck squamous cell carcinoma treated with a cetuximab-based therapy have been shown, EGFR variation could be a useful biomarker for less skin toxicity and poor prognosis (10, 22). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.